Status:
COMPLETED
Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Hepatitis C
Eligibility:
All Genders
18+ years
Brief Summary
Sofosbuvir plus daclatasvir with or without ribavirin is one of the currently recommended treatment option for chronic hepatitis C. The objectives were to identify factors associated with sofosbuvir/d...
Eligibility Criteria
Inclusion
- Patients with hepatitis C virus infection treated with sofosbuvir/daclatasvir
- Patients with at least one measurement of sofosbuvir or daclatasvir plasma concentration
- Follow-up of at least 3 months after the end of treatment
Exclusion
- Patients with severe renal failure (estimated glomerular filtration rate (eGFR)\<30ml/min/1.73m2)
- Patients with liver transplantation during therapy
Key Trial Info
Start Date :
February 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2015
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT03318887
Start Date
February 1 2014
End Date
June 30 2015
Last Update
October 24 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Croix-Rousse Hospital, Hospices Civils de Lyon
Lyon, France